SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0000902664-22-003160
Filing Date
2022-06-03
Accepted
2022-06-03 10:52:44
Documents
1

Document Format Files

Seq Description Document Type Size
1 ZENTALIS PHARMACEUTICALS, INC. p22-1568sc13d.htm SC 13D 66292
  Complete submission text file 0000902664-22-003160.txt   68112
Mailing Address 1000 WINTER STREET C/O MATRIX CAPITAL MANAGEMENT WALTHAM MA 02451
Business Address 1000 WINTER STREET C/O MATRIX CAPITAL MANAGEMENT WALTHAM MA 02451 781-522-4948
Matrix Capital Management Company, LP (Filed by) CIK: 0001410830 (see all company filings)

IRS No.: 043475951 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D

Mailing Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Subject) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91478 | Film No.: 22993262
SIC: 2834 Pharmaceutical Preparations